A study of a new combination for multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study tests a new combination therapy for people with multiple myeloma that has returned or not responded to at least one prior treatment. The goal is to see if the combination (QLS32015 plus other drugs) can effectively control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have multiple myeloma that has come back or gotten worse after at least one prior treatment.
- Your disease is measurable with a blood or urine test (for example, a certain protein level in blood or urine).
- You have not had a serious (Grade 3 or higher) cytokine release syndrome (CRS) reaction with previous T-cell therapies.
- You have not received certain prior myeloma treatments within the specified timeframes before joining (like CAR-T in the last 3 months, or other targeted drugs in the last few weeks).
- You are not allergic or intolerant to any drugs in the specific treatment combination you would receive (like Pomalidomide, Bortezomib, Lenalidomide, or Daratumumab).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, QLS32015, against two common treatments for multiple myeloma that has come back or not responded to therapy. It may be an option for people who have already tried several treatments.
This study tests an investigational drug for people with multiple myeloma, a type of blood cancer. It aims to see how safe and effective the treatment is for patients who are newly diagnosed or have relapsed after prior therapy.
This study tests a combination of four medicines (isatuximab, bortezomib, lenalidomide, dexamethasone) for people with newly diagnosed high-risk multiple myeloma who are not having a stem cell transplant. The goal is to see if this combination can better control the disease and improve outcomes.
This trial tests a new medicine (GR1803) against a standard combination treatment for people whose multiple myeloma has come back or stopped responding to prior therapies. It aims to see if the new drug works better.
This trial tests a combination of three drugs (CM336, daratumumab, and lenalidomide) for people with newly diagnosed multiple myeloma who are not eligible for a stem cell transplant. The goal is to see if this combination is safe and effective in controlling the disease.
This trial tests a new combination treatment for multiple myeloma and similar blood cancers. It aims to see if the combination works better than current options and may help people whose cancer has not responded to other treatments.
Hear when a new Relapsed or Refractory Multiple Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.